NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
34.81
+0.87 (2.56%)
At close: Jan 22, 2026, 4:00 PM EST
34.30
-0.51 (-1.47%)
After-hours: Jan 22, 2026, 6:40 PM EST
NAMS Employees
NewAmsterdam Pharma Company had 77 employees as of March 31, 2025. The number of employees increased by 9 or 13.24% since the number was last reported on December 31, 2024.
Employees
77
Change
9
Growth
13.24%
Revenue / Employee
$457,701
Profits / Employee
-$2,871,078
Market Cap
3.95B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 77 | 9 | 13.24% |
| Dec 31, 2024 | 68 | 39 | 134.48% |
| Dec 31, 2023 | 29 | 12 | 70.59% |
| Dec 31, 2022 | 17 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,609 |
| ADMA Biologics | 685 |
| Corcept Therapeutics | 500 |
| Alumis | 223 |
| Liquidia | 170 |
| Arcellx | 163 |
| Vera Therapeutics | 112 |
| Centessa Pharmaceuticals | 77 |
NAMS News
- 13 days ago - NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities - GlobeNewsWire
- 17 days ago - NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December - GlobeNewsWire
- 2 months ago - NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating - Seeking Alpha
- 2 months ago - NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results - GlobeNewsWire
- 3 months ago - NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November - GlobeNewsWire
- 4 months ago - NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum - GlobeNewsWire